Results 21 to 30 of about 12,754 (124)

Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer—Participation in Pathogenesis or a Possible Clinical Use?

Cells, 2020
Due to the ability to selectively induce apoptosis in cancer cells, the most interesting target for clinical research is the tumour necrosis factor ligand inducing apoptosis (TRAIL), which binds specific receptors, including osteoprotegerin (OPG).
Aleksandra Mielczarek-Palacz, Zdzisława Kondera-Anasz, Marta Smycz-Kubańska   +2 more
doaj   +1 more source

Serous cystadenocarcinoma of the spleen

Radiology Case Reports, 2017
The commonly seen primary malignant neoplasms of the spleen are angiosarcoma and lymphoma. We present a case of serous cystadenocarcinoma of the spleen.
Chung Kuao Chou, MD, Shih-Cheng Chou, MD
doaj   +1 more source

Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature

Rare Tumors, 2011
Papillary serous cystadenocarcinoma of the ovary is a common tumor but occurrence of ovarian type papillary serous cystadenocarcinoma in the testis is very rare. Herein we report such a case in a 49-year-old man presenting with testicular swelling.
Sharhriar Zeighami, Sara Pakbaz, Mohammadreza Farzaneh, Bita Geramizadeh   +3 more
doaj   +1 more source

Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

Journal of Ovarian Research, 2019
Background The role of calcineurin/NFAT signaling in ovarian cancer has been unknown. NFAT was significantly overexpressed in ovarian cancer tissues and that overexpression of NFAT was significantly associated with metastasis and poor prognosis on ...
Bing Xin, Kai-Qiang Ji, Yi-Si Liu, Xiao-Dong Zhao   +3 more
doaj   +1 more source

Histopathological Study of Ovarian Lump and Serum Tumor Marker Ca 125 estimation as a Screening Tool

Journal of Nobel Medical College, 2018
Background: Ovarian tumor is the fourth commonest cancer in female in Nepal. About 80% is benign and 20% of these tumors are malignant. Due to its complex nature, vagueness and non-specificity of the symptoms it produces, the ovarian neoplasm can mislead
Manish Kumar Das, Sita Ghimire
doaj   +1 more source

Clinicopathologic study of malignant ovarian tumors: A study of fifty cases

Medical Journal of Dr. D.Y. Patil University, 2017
Background: Malignant ovarian tumors have worst prognosis among all gynecological malignancies and highest case fatality rate. There is a steady increase in the age-standardized incidence rate in India.
Shirish S Chandanwale, Rahul Jadhav, Ruby Rao, Piyusha Naragude, Sunita Bhamnikar, Jehan Nizam Ansari   +5 more
doaj   +1 more source

A rare case of collision tumor: Massive mucinous cystadenoma and benign mature cystic teratoma arising in the same ovary

CHRISMED Journal of Health and Research, 2017
Collision tumor means the coexistence of two adjacent, but histologically distinct tumors without histologic admixture in the same tissue and is rare incidence involving the ovary.
Reddy Ravikanth
doaj   +1 more source

Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells

Journal of Ovarian Research, 2022
Background Recently, increasing evidence has indicated that elevation of Hexokinase 2 (HK2) plays an important role in several cancers on regulating cell motility and growth.
Xueye Tian, Dan Liu, Xiaohang Zuo, Xiaoli Sun, Mengmin Wu, Xu Li, Yue Teng   +6 more
doaj   +1 more source

Clinical features of the microRNA genes methylation in borderline ovarian tumors and depending on the histological structure in ovarian malignancies

Alʹmanah Kliničeskoj Mediciny, 2022
Background: Borderline ovarian tumors (BOT) belong to the intermediate type between benign and malignant ovarian neoplasms. Serous borderline tumors share common molecular and genetic characteristics with serous carcinomas. An increase in the methylation
Svetlana S. Lukina, Alexey M. Burdennyy, Elena A. Filippova, Irina V. Pronina, Tatiana P. Kazubskaya, Dmitry N. Kushlinsky, Dmitriy O. Utkin, Eleonora A. Braga, Vitaly I. Loginov, Nikolay E. Kushlinskii   +9 more
doaj   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source